StemCell Therapy

The fraternity of baseball players with type 1 diabetes isnt large. Its not unusual for someone to make a connection with someone else through a mutual friend within the group. Thats how former major-league outfielder Sam Fuld remembered getting in touch with Garrett Mitchell a few years ago.

Mitchell, 21, was in high school, a top outfield prospect preparing to attend UCLA, when he first heard from Fuld. One day, Fuld, whose eight-year playing career ended in 2015, phoned him. They shared stories. Fuld was diagnosed with type 1 diabetes when he was 10. Mitchell was 9 when he learned he had diabetes. Fuld offered advice. The two have maintained a relationship. Throughout it, Fuld has learned how well-equipped Mitchell is at handling the disease.

I was impressed with him right away, Fuld said. Just talking to him, he seemed like a mature kid back then. He certainly seemed to have a really good mindset, which is so key in...

See original here:
Brewers' Garrett Mitchell has unique perspective by living with type 1 diabetes - The Athletic

The past decade has seen significant advances in type 2 diabetes treatments, yet the long-term impact of these advances is not yet fully appreciated. The risk estimates currently available are derived from data that is more than 10 years old. The insurance industry underwrites customers with diabetes based on a range of factors, medical expertise and various medical studies.

The aim of this research project is to develop a deeper understanding of the risks associated with type 1 or type 2 diabetes, and the impact of recent improved treatments. It is hoped that this research will help the insurance industry appreciate and use current data and studies when considering diabetic risks, and ultimately could support individuals with diabetes to gain better access to insurance.

The call for tenders was issued on 1 June and organisations have until 12pm BST on 13 July to submit their proposals. This commissioned research will be overseen by a project steering group including representation from the IFoAs Diabetes Working Party and partner organisations. Independent academic guidance is also being provided by Cass Business School, City, University of London.

For further information onthis jointly commissioned ARC research project, please visitbit.ly/arcdiabetes

Read the original post:
An analysis of diabetes mortality and morbidity risk - The Actuary

New Jersey, United States,- Verified Market Research sheds light on the market scope, potential, and performance perspective of the Type 2 Diabetes Treatment Market by carrying out an extensive market analysis. Pivotal market aspects like market trends, the shift in customer preferences, fluctuating consumption, cost volatility, the product range available in the market, growth rate, drivers and constraints, financial standing, and challenges existing in the market are comprehensively evaluated to deduce their impact on the growth of the market in the coming years. The report also gives an industry-wide competitive analysis, highlighting the different market segments, individual market share of leading players, and the contemporary market scenario and the most vital elements to study while assessing the Type 2 Diabetes Treatment market.

The research study includes the latest updates about the COVID-19 impact on the Type 2 Diabetes Treatment sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Leading Type 2 Diabetes Treatment manufacturers/companies operating at both regional and global levels:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Industrial Analysis:

The Type 2 Diabetes Treatment market report is extensively categorized into different product types and applications. The study has a separate section for explaining the cost of raw material and the revenue returns that are gained by the players of the market.

The segmentation included in the report is beneficial for readers to capitalize on the selection of appropriate segments for the Type 2 Diabetes Treatment sector and can help companies in deciphering the optimum business move to reach their desired business goals.

In Market Segmentation by Types of Type 2 Diabetes Treatment, the report covers-

Bytype1

In Market Segmentation by Applications of the Type 2 Diabetes Treatment, the report covers the following uses-

Byapplication1

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=31462&utm_source=3WN&utm_medium=007

The Type 2 Diabetes Treatment market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Type 2 Diabetes Treatment market.

This study analyzes the growth of Type 2 Diabetes Treatment based on the present, past and futuristic data and will render complete information about the Type 2 Diabetes Treatment industry to the market-leading industry players that will guide the direction of the Type 2 Diabetes Treatment market through the forecast period. All of these players are analyzed in detail so as to get details concerning their recent announcements and partnerships, product/services, and investment strategies, among others.

Sales Forecast:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Type 2 Diabetes Treatment market. Additionally, it includes a share of each segment of the Type 2 Diabetes Treatment market, giving methodical information about types and applications of the market.

Reasons for Buying Type 2 Diabetes Treatment Market Report

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It renders an in-depth analysis for changing competitive dynamics.

It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Type 2 Diabetes Treatment market.

This report helps the readers understand key product segments and their future.

Have Any Query? Ask Our Expert @ https://www.verifiedmarketresearch.com/product/Type-2-Diabetes-Treatment-Market/?utm_source=3WN&utm_medium=007

In the end, the Type 2 Diabetes Treatment market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the Type 2 Diabetes Treatment market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

See the original post:
Type 2 Diabetes Treatment Market Growth By Manufacturers, Countries, Types And Application, End Users And Forecast To 2026 - 3rd Watch News

Understanding gestational diabetes

Gestational diabetes can be a scary diagnosis, but like other forms of diabetes, its one that you can manage. It doesnt mean that you had diabetes before you conceived or that you will have diabetes after you give birth. It means that, by working with your doctor, you can have a healthy pregnancy and a healthy baby. No matter what, know that you have all the support you need for both you and your baby to be at your best.

We dont know what causes gestational diabetes, but we know that you are not alone. It happens to millions of women. We do know that the placenta supports the baby as it grows. Sometimes, these hormones also block the action of the mothers insulin to her body and it causes a problem called insulin resistance. This insulin resistance makes it hard for the mothers body to use insulin. And this means that she may need up to three times as much insulin to compensate.

The key to treating it is to act quicklybecause as treatable as it is, gestational diabetes can hurt you and your baby. Work with your doctor to keep your blood sugar levels normal, through special meal plans and regular physical activity. Your treatment may also include daily blood sugartesting and insulin injections.

Read more on gestational diabetes

In addition to type 1, type 2 and gestational diabetes, a small minority of people develop specific types of diabetes due to other causes. This includes:

Because these types of diabetes are rare, they are often misdiagnosed as other types of diabetes. You can learn more about these types of diabetes in the Classification and Diagnosis of Diabetes section in the Standards of Medical Care in Diabetes. If you think you might have one of these types, be sure to talk with your doctor.

More on diabetes from other causes

When it comes to prediabetes, there are no clear symptomsso you may have it and not know it. Heres why thats important: before people develop type 2 diabetes, they almost always have prediabetesblood sugar levels that are higher than normal but not yet high enough to be diagnosed as diabetes. You may have some of the symptoms of diabetes or even some of the complications.

Read more:
Diabetes Overview - Symptoms, Causes, Treatment

China releases genome of latest viral outbreak in Beijing

China has released genome sequencing data from samples taken in Beijing, amid the latest outbreak in the capital.

Virus genome sequencing is a vital and rapidly-developing tool in the diagnosis of COVID-19 and in understanding the spread and control of the new coronavirus as it moves around the globe.

The latest genome sequencing which has been shared with the World Health Organization (WHO) and the Global Influenza Data Initiative (GISAID) has identified a European strain of the virus, according to Chinese officials. But the WHO said that further investigation was needed to understand the origin of the latest outbreak.

Evidence suggests coronavirus might trigger diabetes

Diabetes is a known risk factor for developing severe COVID-19 and people with the condition are more likely to die. Now, some researchers are also pursuing the idea that diabetes doesnt just make people more vulnerable to the coronavirus, but that the virus might also trigger diabetes in some.

Early evidence from tissue studies and some people with COVID-19 shows that the new coronavirus damages insulin-producing cells, which are important for regulating blood sugar levels.

A handful of COVID-19 patients have spontaneously developed diabetes and dozens more have arrived in hospital with extremely high levels of blood sugar and ketones, which are produced from fatty deposits in the liver. When the body doesnt make enough insulin to break down sugar, it uses ketones as an alternative source of fuel.

New findings from experiments on miniature lab-grown pancreases also suggest that the virus might trigger diabetes by damaging insulin-producing cells.

However, in order to prove a causal link between the virus and the onset of diabetes, researchers will need to conduct well-constructed epidemiological cohort studies as well as further lab experiments.

Young people shielded from infection by close contacts

People under the age of 20 are much less likely than their elders to catch the new coronavirus from an infected household member, according to new research led by scientists at the University of Florida and the Center for Disease Control and Prevention in China.

The team analysed viral transmission between infected people in the city of Guangzhou in China and those whod had close contact with them. After public-health officials enforced isolation of infected individuals and quarantine of their contacts, people under the age of 20 had a 5.2% risk of being infected by a member of their household, compared with a 14.8% risk for people aged 2059 and an 18.4% risk for people aged 60 and above.

The researchers also found that people with COVID-19 were at least as infectious before their symptoms started as after, adding to the evidence of asymptomatic and pre-symptomatic viral spread.

The first global pandemic in more than 100 years, COVID-19 has spread throughout the world at an unprecedented speed. At the time of writing, 4.5 million cases have been confirmed and more than 300,000 people have died due to the virus.

As countries seek to recover, some of the more long-term economic, business, environmental, societal and technological challenges and opportunities are just beginning to become visible.

To help all stakeholders communities, governments, businesses and individuals understand the emerging risks and follow-on effects generated by the impact of the coronavirus pandemic, the World Economic Forum, in collaboration with Marsh and McLennan and Zurich Insurance Group, has launched its COVID-19 Risks Outlook: A Preliminary Mapping and its Implications - a companion for decision-makers, building on the Forums annual Global Risks Report.

The report reveals that the economic impact of COVID-19 is dominating companies risks perceptions.

Companies are invited to join the Forums work to help manage the identified emerging risks of COVID-19 across industries to shape a better future. Read the full COVID-19 Risks Outlook: A Preliminary Mapping and its Implications report here, and our impact story with further information.

Majority of infected people never show classic symptoms

More than two thirds of people infected with coronavirus in Lombardy the epicentre of the outbreak in Italy did not display symptoms, according to new unpublished research.

Researchers studied people in Lombardy who had had close contact with an infected person. Roughly half of these 5,484 contacts became infected themselves. Of those, 31% developed respiratory symptoms or a fever and only 26% of those under the age of 60 did so.

As a persons age increased, so did their odds of experiencing symptoms and becoming ill enough to require intensive care, or to die.

Possible higher risk for blood group A

Genome-wide association studies are a relatively new way for scientists to identify genes involved in human disease. This method searches the complete set of genes known as the genome for small variations that occur more frequently in people with a particular disease than in people without the disease.

A genomewide association study involving 1,980 patients with Covid-19 at hospitals in the Italian and Spanish epicentres of the European pandemic, reveals that people with blood type A have an elevated risk compared to non-type A individuals.]

Original post:
COVID-19: Top science stories of the week, including new diabetes link and the latest Beijing - World Economic Forum

The "Diabetes Care Devices Market by Type (SMBG, CGMS, Lancets, Insulin Pumps, Insulin Pens, Insulin Syringes, Mobile Apps), Patient Care Settings (Hospitals & Specialty Clinics, Self & Home Care), and Country (Brazil, Russia, India, China) - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The diabetes care devices (BRIC) market size is projected to reach USD 4.3 billion by 2025 from USD 1.7 billion in 2020, at a CAGR of 16.2% during the forecast period.

The growth in this market is primarily attributed to the sharp increase in diabetes, increasing awareness of diabetes management due to the rising number of diabetes awareness campaigns and screening camps, favorable national health strategies, and government-led endorsement of medical devices.

By type, under the insulin delivery devices segment, insulin pens to hold the largest share during the forecast period

Within the type category, the diabetes care devices (BRIC) market has been segmented into blood glucose monitoring systems, insulin delivery devices, and diabetes management mobile applications. Within the insulin delivery devices segment, insulin pens held the largest share in the market. The increasing affordability of insulin pens, convenience, ease-of-use, and technological advancements in these devices that promote integrated diabetes management support the growth of this segment.

By end-user, the self/ home healthcare segment is expected to grow at a higher rate during the forecast period (2020-2025)

Based on end-user, the diabetes care devices (BRIC) market has been segmented into hospital & specialty clinics and self/home healthcare. The self/home healthcare segment is expected to grow at a higher CAGR due to the increasing awareness of self-management of diabetes, increasing portability of diabetes care devices, and technological innovations that provide real-time insights for patients and healthcare providers for decision-making regarding diabetes control and treatment planning.

India is projected to grow at the highest CAGR

China is expected to account for the largest share of the diabetes care devices (BRIC) market in 2019. The large share of this region can primarily be attributed to the sharp increase in the diabetic population in the past decade and endorsements of medical devices by the government. On the other hand, India is expected to witness the highest CAGR during the forecast period due to the increasing government investment in the medical devices industry, high prevalence of type 1 and gestational diabetes cases, and increasing diabetes awareness creation through campaigns and screening camps.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Industry Insights

6 Diabetes Care Devices Market, by Type

7 Diabetes Care Devices Market, by Patient Care Settings

7.1 Introduction

7.2 Self/Home Healthcare

7.3 Hospitals & Diabetes Specialty Clinics

8 Diabetes Care Devices Market in BRIC Countries

8.1 Introduction

8.2 China: Diabetes Care Devices Market

8.2.1 Introduction

8.2.2 Market Drivers

8.2.2.1 Sharp Increase in Diabetes in the Past Decade

8.2.2.2 Favorable National Health Strategies

8.2.2.3 Government-Led Endorsement of the Medical Device Industry

8.2.3 Market Restraints

8.2.3.1 Traditional Chinese Medicine As an Alternative

8.2.3.2 High Cost of Advanced Diabetes Management Devices

8.2.4 Market Opportunities

8.2.4.1 Significant Advancements and Leveraging of Artificial Intelligence and Big Data

8.2.5 Market Challenges

8.2.5.1 Lack of Adherence of Patients to Recommended Diabetes Treatment Guidelines

8.3 India: Diabetes Care Devices Market

8.3.1 Introduction

8.3.2 Market Drivers

8.3.2.1 High Prevalence of Diabetes

8.3.2.2 Government's Make in India Campaign to Encourage Local Manufacturing of Medical Devices

8.3.2.3 Diabetes Awareness Campaigns and Screening Camps

8.3.3 Market Restraints

8.3.3.1 Lack of Accessibility to Healthcare

8.3.3.2 Inadequate Health Insurance Coverage

8.3.4 Market Opportunities

8.3.4.1 Rising Adoption of Mhealth

8.3.5 Market Challenges

8.3.5.1 Shortage of Healthcare Professionals in Diabetes Management

8.4 Brazil: Diabetes Care Devices Market

8.4.1 Introduction

8.4.2 Market Drivers

8.4.2.1 High Prevalence of Diabetes

8.4.2.2 Favorable Government Policies

Story continues

8.4.3 Market Restraints

8.4.3.1 Lack of Awareness of Diabetes Care

8.4.3.2 High Prices of Advanced Diabetes Care Devices

8.4.4 Market Opportunities

8.4.4.1 Increasing Penetration of Smartphones and Rising Focus on Digital Health to Drive the Growth of Diabetes Management Platforms and Diabetes Management Mobile Applications

8.4.5 Market Challenges

8.4.5.1 Strict Regulatory Guidelines and Regulatory Process for Medical Devices

8.5 Russia: Diabetes Care Devices Market

8.5.1 Introduction

8.5.2 Market Drivers

8.5.2.1 Rising Elderly Population

8.5.2.2 Increasing Rate of Obesity

8.5.3 Market Restraints

8.5.3.1 Large Number of Undiagnosed Diabetics

8.5.4 Market Opportunities

8.5.4.1 Government Spending on Healthcare

8.5.4.2 Rising Investment of Pharma Market Players to Establish Local Manufacturing Plants

8.5.5 Market Challenges

8.5.5.1 Low Adoption of Glucose Monitoring Systems

9 Competitive Landscape

9.1 Overview

9.2 Product Benchmarking

9.3 Geographic Reach of the Top Market Players (2019)

9.4 R&D Expenditure: Key Players in the Diabetes Care Devices (Bric) Market

9.5 Market Share Analysis

10 Company Profiles

10.1 F. Hoffman-La Roche Ltd.

10.2 Abbott

10.3 Ascensia Diabetes Care Holdings Ag

10.4 Dexcom, Inc.

10.5 Medtronic Plc

10.6 B. Braun Melsungen Ag

10.7 Becton, Dickinson and Company

10.8 Acon Laboratories, Inc.

10.9 Arkray, Inc.

10.10 Sanofi

10.11 Novo Nordisk A/S

10.12 Terumo Corporation

10.13 Ypsomed

10.14 Sinocare, Inc.

10.15 Agamatrix Holdings Llc

10.16 Lifescan

10.17 Sd Biosensor, Inc.

10.18 Microgene Diagnostic Systems Pvt. Ltd.

10.19 Dr. Morepen

10.20 Bionime Corporation

See original here:
Diabetes Care Devices Market by Type, Patient Care Settings, and Country - BRIC Forecast to 2025 - ResearchAndMarkets.com - Yahoo Singapore News

Vancouver, British Columbia--(Newsfile Corp. - June 29, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)("PreveCeutical"), is pleased to announce that it has successfully designed, screened and shortlisted a panel of smart-siRNA constructs with potent gene silencing activity (in vitro) in its Dual Gene Therapy Research Program.

This further update to the Company's Dual Gene Therapy Program, (see earlier release on January 14, 2020), is an important and fundamental aspect which involves deriving Smart-siRNA constructs, effective in downregulating the Company's target gene of interest, in type 2 diabetes and obesity.

The Company is very pleased to confirm that it has now shortlisted a panel of Smart-siRNA constructs considered novel in their sequence and chemistry. The panel of Smart-siRNA constructs incorporate a proprietary chemistry, adding to their novelty. In the next phase, this construct's biostability will be essential for assessment in preclinical (mice) models of type 2 diabetes and obesity.

The Company can confirm that a number of siRNA drug delivery systems were evaluated in a 3-dimensional liver tissue assay. The 3D liver tissue assay mimics the 3D architecture and microenvironment of the liver, so it is closer to the real-life biological environment than the 2D testing. Ongoing work aims to determine the optimal drug delivery technology with the Smart-siRNA with the desirable properties, including biostability, the release of the siRNA cargo when exposed to physiological intracellular conditions and no evidence of cellular toxicity.

The Company may consider filing a patent application to protect the siRNA sequences, the Smart-siRNA constructs and related intellectual property arising from this Program.

The Company's President and Chief Scientific Officer, Dr. Makarand Jawadekar, commented, "We are very happy with the progress of our Programs to date with UniQuest. The outcomes from this Program will definitely add IP to PreveCeutical's growing IP portfolio, enhancing our "out-licensing" technologies strategy with bigger Pharma companies and helping their commercialization of new products".

About PreveCeutical

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

PreveCeutical aims to be a leader in preventive health sciences. The Company's current research and development programs include dual gene curative and preventive therapies for diabetes and obesity; the Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders.; Nature Identical peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

For more information about PreveCeutical, please visit our website http://www.PreveCeutical.com or follow us on Twitter and Facebook.

On behalf of the Board of Directors of PreveCeutical

Stephen Van Deventer, Chairman and Chief Executive Officer

For further information, please contact:

Stephen Van Deventer: +1 604 306 9669

Or Investor Relations ir@preveceutical.com

Forward-Looking Statements:

This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, the completion of one aspect of the current phase of the Dual Gene Therapy Program, the efficacy of the Company's products, matters related to the Company's current and planned research and development programs, including the Dual Gene Therapy Program, the efficacy of the panel of siRNA constructs and the efficacy, biostability and potency of the Smart-siRNAs, the Company's anticipated future business plans and its prospect of success in executing thereon. Often, but not always, forward-looking statements can be identified by words such as "will", "plans", "expects", "may", "intends", "anticipates", "believes", "proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding the Company, including expected growth, results of operations and research and development activities (including in respect of the successful completion of the Dual Gene Therapy Program and one aspect of its current phase), performance, industry trends, growth opportunities, and that the Company will be able to obtain the financing required to carry out its planned future business activities, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights it needs to carry out its future business activities.

Story continues

Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to the completion of the Dual Gene Therapy Program and one aspect of its current phase, actual results of research and development programs, the inability of the Company, to, among other things, protect its intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities, commercialize any therapeutic and diagnostic technologies, execute its proposed business plans, pursue business partnerships, complete its research and development programs as planned, including the Dual Gene Therapy Program, and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology, pharmaceutical or cannabis industry may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, intentions and assumptions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, intentions or assumptions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company's filings are available at http://www.sedar.com.

Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/58765

See the rest here:
PreveCeutical Announces Promising 3D Liver Tissue Testing of Potential Therapy for Diabetes and Obesity - Yahoo Finance

To discourage people with hypertension and diabetes from visiting government hospitals amid rising cases of COVID-19, the Health department is delivering medicines at their doorsteps.

Doctors and officials have stressed that COVID-19 patients with co-morbidities are at higher risk of developing complications. The elderly and those with co-morbidities have been advised to stay indoors. Besides, during the lockdown from March 23 to May 31, people found it hard to get medicines as transportation also come to a halt.

Officials from the Commissioner of Health and Family Welfare wing said they initiated the process of delivering medicines at the doorstep of patients from March year when coronavirus cases had started to emerge in Telangana.

Under Non Communicable Disease (NCD) screening programme last year, 1.1 crore adults were screened for the two diseases. Of them, around 10.98 lakh with hypertension and 5.50 lakh with diabetes were diagnosed, and receiving treatment in both public and private healthcare facilities.

After initial screening of people above the age of 30 years by Auxiliary Nursing Midwives (ANMs), if abnormal blood pressure or blood sugar levels are recorded, the person is referred to Primary Health Centre (PHC) medical officer who conducts another round of diagnosis to confirm the readings. If abnormalities are recorded, the patient is put on treatment.

Till mid-2019, medicines for NCD were distributed to patients on a monthly basis at Primary Health Centres (PHC).Thereafter, the distribution process was decentralised in Telangana, under the India Hypertension Control Initiative.

Refilling drugs was shifted to sub-centres through ANMs so that patients, especially the elderly who constitute a majority of the patients, dont have to travel long distances to reach a PHC for the medicines or check-ups.

If the readings were not abnormal during subsequent check-ups, medicines were issued based on prescription issued by PHC Medical officer. Officials said they issued treatment booklets with details of blood pressure or blood sugar readings, medicines issued, etc. However, if ANMs recorded abnormal readings during the subsequent check-ups, the patients were again referred to the PHC medical officer who further examined and escalated the drugs, if necessary.

However, after imposition of lockdown, patients were unable to travel to get medicines. So, a decision was taken to deliver drugs on a monthly basis by the ANMs to their doorstep. The number of diabetes and hypertension patients receiving treatment in the government sector was 6.5 lakh in March which increased to 8.27 lakh in April and was estimated to be around 8.7 lakh for May 2020, Health officials said.

As ANMs go door to door to deliver medicines, they are provided masks, face shields and gloves.

You have reached your limit for free articles this month.

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Enjoy reading as many articles as you wish without any limitations.

A select list of articles that match your interests and tastes.

Move smoothly between articles as our pages load instantly.

A one-stop-shop for seeing the latest updates, and managing your preferences.

We brief you on the latest and most important developments, three times a day.

Not convinced? Know why you should pay for news.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Continue reading here:
Medicines at the doorstep for those with hypertension and diabetes - The Hindu

The global wound closure products market is a highly competitive market with a high number of global and local players operating in it around the world, states a new market research study by Transparency Market Research. The key players in the market are focusing on the expansion of the product portfolio and the innovations, which is expected to support the growth of the overall market in the next few years. In addition to this, the rising research and development activities and technological developments are projected to enhance the growth of the market in the next few years.

Furthermore, the rising collaborations and mergers and acquisitions are projected to generate potential growth opportunities for the market players throughout the forecast period. Some of the key players operating in the wound closure products market across the globe are Covidien plc, Baxter International, Inc., Johnson & Johnson (Ethicon), B. Braun, and Cryolife.

According to the market research study by Transparency Market Research, the global market for wound closure products is expected to reach a value of US$15.2 bn by the end of year 2023. The market is estimated to register a promising growth rate throughout the forecast period.

Request Brochure of Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5429

High Contribution from US to Drive North America Wound Closure Products Market

Among the key regional segments, North America is expected to hold a large share of the market and is likely to remain in the leading position throughout the forecast period. The launch of new medical devices and the rising contribution from the U.S. are some of the key factors that are estimated to enhance the growth of this region in the next few years. In addition to this, the well-established healthcare sector and the presence of several leading players are some of the other key factors that are estimated to support the growth of the North America market in the next few years.

Furthermore, Europe is likely to remain at the second position with a significant share of the global market. However, Asia Pacific is estimated to offer lucrative opportunities for the players, thanks to which, this region is likely to register a strong growth rate throughout the forecast period.

Request for Analysis of COVID19 Impact on Wound Closure Products Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=5429

The global market for wound closure products on the basis of product type into surgical staples, adhesive and tissue sealants, sutures, and hemostats. Among these, the surgical staples and sutures are considered the key segments and are projected to account for a large share of the overall market in the next few years. On the other hand, with the help of technological advancements, the sealants segment is predicted to witness a healthy growth rate in the next few years. The advent of new products, thanks to the rising research and development activities is predicted to enhance the growth of this segment throughout the forecast period.

Advent of New Products to Enhance Growth of Global Wound Closure Products Market

The rising application in external as well as internal wounds and the increasing number of surgical procedures are considered as the major factors that are projected to enhance the growth of the global wound closure products in the next few years. In addition to this, the rising demand for cosmetic and plastic surgeries is another key factor that is likely to encourage the growth of the overall market throughout the forecast period.

Buy Wound Closure Products Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=5429&ltype=S

The increasing focus of key players on the research and development activities is expected to accelerate the market growth in the near future. Furthermore, the introduction of new products and the rapidly rising geriatric populations are predicted to generate potential growth opportunities for the market players in the next few years.

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 Sate Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

See more here:
Wound Closure Products Market: Increased Prevalence of Diabetes and Disabilities to Bolster Demand - Cole of Duty

Wearing comfortable and well-fitted shoes is necessary and can make your feet healthy and manage the symptoms of diabetes. Here are a few things you must look for in your shoes:

Your shoes should be 1/4 to 1/2 inch deeper than normal shoes so that you do not feel uncomfortable when dealing with calluses or hammertoes.

Instead of pointed toes, buy the one with a spacious toe box. This is will give enough room to your toes to move and reduce the chance of corns, calluses, and blisters.

Avoid high-heel and high-heeled shoes as they put excessive pressure on your foot.

Do not buy any fancy, strappy and open toe shoes. The straps put pressure on certain points of your feet, which can easily cause blisters. Even slippers are not the best option. Wear laced shoes as they provides better support and fit your feet perfectly.

Whenever planning to buy new shoes, do it at the end of the day. Our feet are swollen at the end and if your shoes fit in at that time, you would not have any problem later.

Read more:
Diabetes and foot problems: How to choose the right kind of footwear when suffering from diabetes - Times of India

The recent resurgence in diabetes-related lower-extremity amputations in the United States is not limited to younger adults, according to the author of a recent study that documents similar increases among an older population of Medicare beneficiaries.

While the rate of amputations fell among these older adults from 2000 to 2009, it increased significantly from 2009 to 2017, albeit at a "less severe rate" than recently reported in younger populations, said study investigatorJessica Harding, PhD.

The rate of nontraumatic lower extremity amputation (NLEA) was ticking upward by more than 1% per year over the 2009-2017 period, according to Dr. Harding, assistant professor in the department of surgery at Emory University, Atlanta.

This latest report follows one from last year, published in Diabetes Care, that documented an annual percentage increase approaching 6% between 2009 and 2015, driven by larger increases among adults 18-64 years of age, as well as an increase among men.

It's not clear why rates of NLEA would be on the rise among younger and older adults in the United States, Dr. Harding said, though factors she said could be implicated include changes in amputation practice, increased comorbidities, higher insulin costs, or shortcomings in early prevention programs.

"We need large-scale studies with granular data to tease out key risk factors that could help identify the drivers of these increases in amputations," Dr. Harding said in a presentation at the virtual annual scientific sessions of the American Diabetes Association.

"In the interim, increased attention to preventive foot care across the age spectrum could benefit adults with diabetes," she added.

The latest findings from Dr. Harding and coauthors emphasize the importance of a "team approach" to early prevention in older adults with diabetes, said Derek LeRoith, MD, PhD, director of research in the division of endocrinology, diabetes, and bone diseases with Icahn School of Medicine at Mount Sinai, New York.

"If you take a 75-year-old or even an 80-year-old, their life expectancy can still be a good 10 years or more," Dr. LeRoith said in an interview. "We shouldn't give up on them we should be treating them to prevent complications."

Lower-extremity amputation is a "particularly devastating" complication that can compromise mobility, ability to exercise, and motivation, according to Dr. LeRoith, lead author of a recent Endocrine Societyclinical practice guidelinethat urges referral of older adults with diabetes to a podiatrist, orthopedist, or vascular specialist for preventive care.

"Quite often, treating their glucose or high blood pressure will be much more difficult because of these changes," he said.

Rates of NLEA declined for years, only to rebound by 50%, according to authors of a recent analysis of Nationwide Inpatient Sample (NIS) data reported last year. In their report, the age-standardized diabetes-related NLEA rate per 1,000 adults with diabetes went from 5.30 in 2000, down to 3.07 in 2009/2010, and back up to 4.62 by 2015 (Diabetes Care. 2019 Jan;42:50-4).

The resurgence was fueled mainly by an increased rate of amputations in younger and middle-aged adults and men, and through increases in minor amputations, notably the toe, according to the investigators. "These changes in trend are concerning because of the disabling and costly consequences of NLEAs as well as what they may mean for the direction of efforts to reduce diabetes-related complications," authors of that report said at the time.

In the current study, Dr. Harding and colleagues included Medicare Parts A and B claims data for beneficiaries enrolled from 2000 to 2017. There were 4.6 million Medicare fee-for-service beneficiaries with diabetes in 2000, increasing to 6.9 million in 2017, she reported at the virtual ADA meeting.

Rates of NLEA followed a trajectory similar to what was seen in the earlier NIS report, falling from 8.5 per 1,000 persons in 2000 to 4.4 in 2009, for an annual percentage change of 7.9 (P< .001), Dr. Harding said. Then rates ticked upward again, to 4.8 in 2017, for an annual percentage change of 1.2 over that later period (P< .001).

While the trend was similar for most subgroups analyzed, the absolute rates were highest among men and black individuals in this older patient population, reported Dr. Harding and coauthors.

Dr. Harding said she and coauthors had no disclosures related to the research, which was performed as a collaboration between Emory University and the Centers for Disease Control and Prevention Division of Diabetes Translation.

SOURCE:Harding J. ADA 2020,Abstract 106-OR.

This article originally appeared onMDedge.com.

See the rest here:
Diabetes-Related Amputations on the Rise in Older Adults - Medscape

Today, formulas like Divine Bounty B Vitamin Complex continue to be a popular choice among health-conscious and budget-wise consumers.

(Newswire.net -- June 29, 2020) Orlando, FL -- Today, diabetes is prevalent not just in the United States but in many areas around the globe. Diabetes is undeniably widely researched on nowadays. However, it is also important to note that it has not been identified yet what causes the condition.

There are actually possible culprits, such as insulin resistance. It is worth leaning insulin permits glucose from food to enter the cells for energy supply. There are factors found to contribute to insulin resistance, such as the bodys attempt to produce extra insulin for the purpose of processing excess blood glucose.

It could also be influenced by genetic or environmental factors. According to experts, over time, insulin turns less effective at introducing glucose to cells, and this causes a spike on blood sugar levels.

Experts have been investigating on the various techniques to better manage the condition. It is worth realizing that in addition to following healthy dietary and lifestyle habits, it is also wise to ensure the body has adequate levels of B vitamins.

According to researchers, individuals with diabetes are highly susceptible to having vitamin B12 deficiency. This is due to the fact that certain medications for the condition cause the depletion of this nutrient.

Once vitamin B12 develops, it leads in symptoms like weakness, tiredness, weight loss, loss of appetite, and constipation.

It is also worth being warned that scientists have found a link in between B12 deficiency and diabetic neuropathy. This diabetes complication can affect various body parts, including the gastrointestinal tract.

Some studies also suggest intake of B vitamins may help reduce the odds of having the condition.A study was presented in Nutrition 2019.

In this research, it has been found there is a link between intake of vitamins B2 and B6 with a reduced risk of type 2 diabetes.

Scientists continue to carry out studies to look into the various aspects of diabetes and how it can be managed well.

As the outbreak continues to cause a scare around the world, experts strongly recommend that individuals with this chronic ailment take more precautionary measures to protect themselves. It is worth mentioning the virus could worsen this condition.

The general population is actually advised to take measures in boosting immunity. It is worth mentioning that adequate intake of B vitamins has also been found useful in protecting and enhancing immune system health.

Today, formulas like Divine Bounty B Vitamin Complex continue to be a popular choice among health-conscious and budget-wise consumers.

It contains Choline, Pantothenic acid, Biotin, Vitamin B12, Folic Acid, Niacin, Riboflavin, Thiamin, and vitamin B6. This formula may be a useful source of B vitamins, especially for individuals with diabetes (https://amazon.com/dp/B07414752B).

Divine Bounty is a family-owned brand that manufactures high-quality turmeric curcumin supplements. Passionate about the potential health benefits of turmeric, the team behind Divine Bounty have carefully researched and sourced only the best ingredients to create the ideal blend of turmeric curcumin. More details are available at http://www.DivineBounty.com.

See the original post here:
B Vitamins Found to Have Diabetes-Fighting, Immunity-Protecting Benefits - Newswire

Diabetes is a major cause of death and disability in countries on a Western diet high in animal products, sugar, added oil and processed food. Todays column will discuss what diabetes and prediabetes are and what causes them; next weeks column will discuss how to prevent and reverse type 2 diabetes.

Its important first to understand what glucose and insulin are. In his book How Not to Die, Dr. Michael Greger notes that glucose is the primary fuel powering all the cells in your body, and he defines insulin as the key that unlocks the doors to your cells to allow glucose to enter. For optimal health, its important that blood glucose stays within certain parameters, and insulin made by the beta cells in the pancreas is secreted as needed to regulate blood sugar. Diabetes is the disease that results when blood sugar levels arent kept in check.

Chronic blood sugar elevation damages blood vessels throughout the body, leading to several complications including cardiovascular disease (heart attacks and strokes); eye disease that can lead to blindness; kidney failure; erectile dysfunction; neuropathy (nerve damage) in the feet and legs and throughout the body; peripheral vascular disease that can lead to amputation of the toes and feet; poor wound healing; and dementia. It can also contribute to depression; increased risk of blood clots; increased harmful inflammation; and weakened immunity.

There are two types of diabetes. Five percent of diabetic cases in the U.S. are type 1, which is an autoimmune disease where a subjects immune system goes rogue and attacks the insulin-producing beta cells in the pancreas. Type 1 can have a genetic component, and is not related to lifestyle, although all autoimmune diseases are more prevalent in societies on a Western diet. Type 2 diabetes accounts for 95 percent of diabetes in the U.S., and is clearly a lifestyle disease. This column is primarily about type 2 diabetes.

Support Local JournalismDonate

According to the CDC, approximately 50% of Americans have either prediabetes or diabetes, and the prevalence increases yearly as Americans get heavier. We used to call type 2 adult onset diabetes, but we cant use that term any longer because so many of our kids are now overweight and have type 2 diabetes. Prediabetes is a misnomer because it is not really pre-disease but rather is a mild form of diabetes. Prediabetes causes the same, aforementioned, complications that actual diabetes does.

Prediabetes/type 2 diabetes are caused by insulin resistance (I.R.) where fat in and around organs and muscles prevents insulin from entering cells and doing its job. The insulin resistance-causing type of fat is called central obesity, or extra weight around the middle. Measure your waist at the level of maximum circumference (approximately at the level of your belly button). If youre a man and the measurement is 40 inches or greater, or a woman and it is 35 inches or greater, you have insulin resistance with lower cutoffs for Asians and East Indians. Even if you dont meet those criteria, but have even a little belly when you look at your naked profile in the mirror, you probably have I.R.

Your pancreas tries to compensate for insulin resistance by pumping out more and more insulin, and over the years the beta cells eventually wear out and are destroyed. Unfortunately, diabetes often isnt diagnosed until the fasting blood sugar becomes 126 or greater, and by then significant damage has already been done in the form of the complications mentioned in the third paragraph. Because some 70 percent of cardiovascular disease is caused by I.R., heart attack prevention doctors look for early signs, such as high triglycerides and low HDL (triglyceride/HDL ratio of 3.5 or greater), and small, dense LDL (bad cholesterol) particles. The gold standard test for early diagnosis is a one- and two-hour glucose tolerance test: fast 12 hours, drink a 75 gram glucose load, and if your blood sugar one hour later is 125 or greater or two hours later 120 or greater, you have insulin resistance/prediabetes. If the two-hour result is 200 or over, you have diabetes.

Another blood test thats used frequently to diagnose diabetes is the A1C, which reflects the average blood sugar level over the previous three months. A normal A1C is < 5.7; prediabetes is 5.7 to 6.5, and 6.5 or above is diabetes. Although this is a useful test to follow diabetics, many heart attack prevention doctors feel it is not accurate for diagnosing prediabetes or diabetes.

Greg Feinsinger, M.D. is a retired family physician who has a nonprofit: Prevention and Treatment of Disease Through Nutrition. He is available by appointment for free consultations (379-5718).

The rest is here:
Doctor's Tip: Diabetes and prediabetes what they are and what causes them - Glenwood Springs Post Independent

According to recent estimates, colorectal cancer (CRC) ranks as the fourth most common cancer in the United States and the second most lethal. Colonoscopy screening has been considered the gold standard for CRC screening because it enables clinicians to view the entire colon and to detect and remove polyps during the same procedure to reduce subsequent risks of CRC. Despite the effectiveness of CRC screening, the American Cancer Society projects that more than 50,000 people in the U.S. die annually from the disease.

Beyond the established risk factors for CRC like advanced age, smoking, and a familial history of the disease, recent studies have suggested that people with diabetes have a higher risk of developing CRC when compared to those without the disease, says Joshua D. Miller, MD. Studies have been conducted to address the association between diabetes and adenoma detection rate (ADR) but results from these clinical trials have been mixed. We need a better understanding of the role of type 2 diabetes in colorectal adenoma-carcinoma progression since diabetes affects nearly 10% of the U.S. population, or over 33 million Americans, adds Dr. Miller.

A New Analysis

For a study published in Scientific Reports, Dr. Miller and colleagues conducted a retrospective review of initial screening colonoscopies while attempting to control for confounding variables. In addition, the authors analyzed the effect of anti-diabetes medications and glycemic control as measured by fasting plasma glucose (FPG) on the day of the colonoscopy and within 12 months of the procedure. Of the 2,865 screening colonoscopies assessed in the study population, 282 were performed on patients who had type 2 diabetes. Of these, 9.8% had type 2 diabetes while 2.4% had type 1 diabetes. Patients with diabetes were often treated with more than one medication.

Our data showed that patients with diabetes had a significantly higher prevalence of adenomas and advanced adenomas than those without it, Dr. Miller says. In a multivariable analysis, the study demonstrated that type 2 diabetes was associated with an increased ADR (odds ratio, 1.49), along with other factors, including smoking, older age, higher BMI, and male sex (Table). Type 2 diabetes was not significantly associated with advanced ADR after taking multiple confounding variables into consideration. However, other factors were significantly associated with an increased advanced ADR, including older age, male sex, smoking and increased BMI. For patients with type 2 diabetes, those not taking diabetes medications were more likely to have an adenoma than those taking these therapies (odds ratio,2.38).

Assessing Implications

Results from the study suggest that type 2 diabetes is significantly associated with an increased risk of detecting at least one adenoma. In addition, two potentially modifiable variables were detected in increased BMI and smoking, both of which were significantly associated with increased ADR and advanced ADR.

Early interventions for preventing type 2 diabetes, attention to glycemic control, and prescribing medications that treat the disease and its secondary complications may reduce risks for developing colonic adenomas, says Dr. Miller. Such efforts may also contribute to better CRC prevention. Clinicians should be aware of the association between diabetes and colorectal adenomas and perhaps recommend more frequent CRC screening in appropriate patients with diabetes. We should seize every opportunity to encourage patients to make lifestyle changes that can help reduce their risks for both CRC and diabetes.

Of note, Dr. Miller and colleagues are conducting a prospective study in which patients with diabetes who are undergoing an initial screening colonoscopy will have their fasting insulin, C-peptide, and A1C levels measured prior to the procedure. Our goal is to collect data on the biochemical components of diabetes and CRC, says Dr. Miller. We hope to establish the extent to which insulin resistance and/or hyperinsulinemia or other factors contribute to the increased risk of developing adenomas in a diverse patient group. This information may provide data on the specific pathways of diabetes and CRC progression and potentially help inform treatment decisions in the future.

Ottaviano LF,Li X,Murray M, et al. Type 2 diabetes impacts colorectal adenoma detection in screening colonoscopy. Sci Rep.2020;10(1):7793. Available at: https://www.nature.com/articles/s41598-020-64344-2.

Larsson SC,Orsini N,Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(22):1679-1687.

Dash C, Palmer JR,Boggs DA,Rosenberg L,Adams-Campbell LL. Type 2 diabetes and the risk of colorectal adenomas: Black Womens Health Study. Am J Epidemiol. 2014;179:112-119.

Onitilo AA, Stankowski RV,Berg RL,et al. Type 2 diabetes mellitus, glycemic control, and cancer risk. Eur J Cancer Prev. 2014;23:134140.

See more here:
The Impact of Type 2 Diabetes on Colorectal Cancer Detection - Physician's Weekly

Patients with diabetes and comorbid depressive disorders may have higher rates of macrovascular complications and all-cause mortality, according to the results of a cohort study conducted with Taiwans National Health Insurance Research Database (NHIRD) and published in Epidemiology and Psychiatric Sciences.

The investigators sought to evaluate whether the presence of depression increases an individuals risk for complications from diabetes and mortality among incident patients with diabetes. Through the NHIRD, they identified incident patients with diabetes 20 years of age. The first date of a patients antidiabetic prescription was defined as the cohort entry date. Individuals with macrovascular or microvascular complications before or on the cohort entry date, as well as those with a diagnosis of schizophrenia or bipolar disorder, were excluded from the study. The composite study endpoint was the development of macrovascular and microvascular complications, cause-specific mortality, and all-cause mortality.

The current study enrolled a total of 38,537 incident patients with diabetes who had depressive disorders and 154,148 patients with diabetes without depression. All participants were randomly selected and matched according to sex, age, and cohort entry year. The average study follow-up time was 5.5 years (range, 0 to 14 years); the mean age of the participants was 52.6112.45 years; and 39.63% were male.

The crude incidence of macrovascular complications was 74.65 per 1000 person-years among those with diabetes and comorbid depressive disorders, which was higher than the incidence of 54.65 per 1000 person-years reported among patients without depression. Similar findings were reported with respect to the crude incidence of mortality due to cardiovascular disease (2.58 per 1000 person-years vs 2.29 per 1000 person-years, respectively); unnatural mortality (2.46 per 1000 person-years vs 0.77 per 1000 person-years, respectively); suicide (1.41 per 1000 person-years vs 0.27 per 1000 person-years, respectively); and all-cause mortality (21.91 per 1000 person-years vs 15.96 per 1000 person-years, respectively). No differences were shown between the groups regarding microvascular complications and mortality due to diabetes.

Following adjustment for covariates, participants with diabetes and comorbid depression had a significantly higher risk for developing macrovascular complications (hazard ratio [HR], 1.35; 95% CI, 1.32 to 1.37), unnatural mortality (HR, 2.59; 95% CI, 2.30 to 2.91), suicide (HR, 5.64; 95% CI, 4.70 to 6.77), and all-cause mortality (HR, 1.08; 95% CI, 1.04 to 1.12). In contrast, no statistically significant differences in microvascular complications or death due to cardiovascular disease were observed between the groups.

The investigators concluded that additional research is warranted, focusing on the risks and the benefits of treatment for depression on outcomes among individuals with diabetes. They noted that the study was limited by potential inclusion of patients who were not diagnosed with or treated for depression in the comparison group. Information on smoking, body weight, exercise routines, and diet control were not available in NHIRD as well.

The researchers concluded, Although we could not directly measure lifestyle behaviours in this study, we found that patients with depression had a higher prevalence of dyslipidemia, alcohol- or substance-related disorders and chronic pulmonary diseases, which are highly related to an unhealthy lifestyle.

Reference

Wu C-S, Hsu L-Y, Wang S-H. Association of depression and diabetes complications and mortality: a population-based cohort study [published online Jan 29, 2020]. Epidemiol Psychiatr Sci. 2020;29:e96. doi: 10.1017/S2045796020000049.

Go here to see the original:
Comorbid Diabetes and Depression Lead to More Complications, Mortality - Psychiatry Advisor

Almost a fifth of people who have died from COVID-19 in Scottish hospitals also had diabetes, new figures have suggested.

The numbers, which do not differentiate between type 1 and type 2 diabetes, show that up until May 24, 554 people who passed away from coronavirus had diabetes mentioned on their death certificate.

This means that almost 15 per cent of the 3,779 coronavirus deaths at that time were related to diabetes.

The data, obtained by the PA News agency from the National Records of Scotland, has prompted Diabetes Scotland to urge the government to reassess the current guidelines for people with the condition as lockdown measures are eased.

At the moment, people with diabetes do not feature on the list that has been put forward for shielding at home.

Angela Mitchell, national director of the organisation, said: The recent statistics underline the urgent need to ensure people with diabetes are protected and supported, especially as lockdown measures are eased.

There must be assurances that people with diabetes should not be put in a situation that puts them at risk at work.

Employers must put measures in place to keep people with diabetes safe, either by supporting people to work at home or, where this is not possible, by putting people with diabetes on furlough or by putting measures in place to allow stringent social distancing for those key workers who absolutely must be at work.

We need to make sure that the new government workplace guidelines work for people with diabetes.

In addition, the figures show that 10 per cent of coronavirus related care home deaths had diabetes and 14 per cent of those who passed away at home from the killer virus were thought to have diabetes too.

A Scottish government spokesman said: We recognise the challenges faced on a daily basis by people living with diabetes. Specific support programmes are in place for people living with type 1 and type 2 diabetes.

We keep all clinical guidance under review and continue to work with our advisors including a specific diabetes speciality advisor. If anyone with diabetes has any concerns about their condition, they should contact their GP or their diabetes clinical team.

They will be able to provide specific advice and support based on their individual circumstances.

View post:
One fifth of COVID-19 hospital deaths in Scotland related to diabetes - Diabetes.co.uk

Chenghui Zhang, Suyuan Wang, Mingxia Li, Yunhong Wu

Department of Endocrinology and Metabolism, Hospital of Chengdu Office of Peoples Government of Tibetan Autonomous Region, Chengdu, Peoples Republic of China

Correspondence: Yunhong WuDepartment of Endocrinology and Metabolism, Hospital of Chengdu Office of Peoples Government of Tibetan Autonomous Region, No. 20 Ximianqiao Street, Chengdu, Sichuan 610041, Peoples Republic of ChinaEmail Wu_yunhong@163.com

Aim: To explore the association between the atherosclerosis and diabetic retinopathy (DR) in Chinese patients with type 2 diabetes mellitus (T2DM).Methods: This hospital-based cross-sectional study included 949 patients (700 males and 249 females) with T2DM. The atherosclerotic parameters were assessed using the cardio-ankle vascular index (CAVI), ankle-brachial index (ABI), and carotid plaque. DR was assessed and graded using digital retinal photography and fundus fluorescein angiography as either nonproliferative DR (NPDR) or proliferative DR (PDR). Multiple logistic regression analysis was performed to identify the associations between the atherosclerotic parameters and DR status.Results: The prevalence of DR was 23.6% in total patients, including 167 (17.6%) patients with NPDR and 57 (6.0%) patients with PDR. Patients with NPDR and PDR were more likely to have higher prevalence of increased CAVI, increased ABI, and carotid plaque than those without DR. In multivariable adjusted logistic regression analysis, patients with NPDR showed an odds ratio (OR) of 2.59 [95% confidence interval (CI), 1.61 4.19] for increased CAVI, 1.99 (0.62 6.34) for increased ABI, and 1.75 (1.13 2.71) for carotid plaque. Patients with PDR showed an OR of 7.83 (3.52 17.41) for increased CAVI, 10.65 (3.33 34.04) for increased ABI, and 11.40 (2.67 48.63) for carotid plaque.Conclusion: Both NPDR and PDR were independently associated with increased CAVI and presence of carotid plaque in Chinese patients with T2DM.

Keywords: atherosclerosis, cardio-ankle vascular index, diabetic retinopathy, ankle-brachial index, carotid plaque

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

View original post here:
Association Between Atherosclerosis and Diabetic Retinopathy in Chines | DMSO - Dove Medical Press

Researchers have identified a bunch of districts in India that have the maximum prevalence for diabetes among women. At least 50 of the 640 districts studied have high prevalence of diabetes greater than one in 10 among women aged 35-49 years. Tamil Nadu, Kerala, Andhra Pradesh and Odisha have districts with the highest prevalence. The results were published in the Journal of Diabetes & Metabolic Disorders.

While Cuttack in Odisha has the highest prevalence of 20%, 14 districts in Tamil Nadu the maximum among all States have high prevalence, prompting the researchers to classify them as hotspots.

Also read: Coronavirus | Are diabetics more prone to COVID-19?

In all, 254 districts have a very high level (greater than 10.7%) of diabetes burden, and 130 have a moderately high (8.7-10.6%) burden. The burden is higher in the southern and eastern parts of the country and lowest in central India.

The researchers sourced data from the National Family Health Survey-4 (2015-16) as it provides district-level health indicators for women. Demographic details of 2,35,056 women from 36 States/Union Territories were analysed for gleaning disease spread and analysing relationship among disease and socio-economic category, location, number of children, obesity and hypertension among others. This was also the first NHS survey to collected blood glucose levels in men and women thus helping determine diabetes.

Results portray that prevalence of diabetes among women in their late reproductive ages is highest among those with two or fewer children ever born, who are educated, belonging to economically prosperous households, living in urban areas and hence enjoying changing lifestyle... increased access to high energy (refined and processed) food and development, the authors Shrikant Singh, Parul Puri and S.V. Subramanian note. Parul Puri and Shrikant Singh are at the International Institute for Population Sciences, Mumbai, and S.V.Subramanian is at Harvard University, Boston, U.S.

Previous studies of the incidence of diabetes in men and women in India have thrown up mixed results with some finding greater evidence of the disease in women, in North India, and others reporting men in South India as more susceptible. However, a skewed gender ratio as well unequal access to medical care has led to the disease being under-reported in women, says a 2014 article in the Indian Journal of Endocrinology and Metabolism.

The study focused on women who were approaching menopause, which was also a period when the risk of obesity, hypertension rose as well as complications from late pregnancy, Ms. Puri told The Hindu. It also provided a greater perspective on why mortality from diabetes is higher among women. Knowing this will help design programmes and interventions to lower community-based prevalence of diabetes, especially among women in their late reproductive ages.

Previous work had found that diabetes-related mortality is higher among women in India. According to Ms. Puri, the prevalence of diabetes among women in India didnt substantially differ from that of men.

The number of people with diabetes in India increased from 260 million in 1990 to 65 million in 2016. The prevalence of diabetes in adults aged 20 years or older in India increased from 55% in 1990 to 77% in 2016. The prevalence in 2016 was highest in Tamil Nadu and Kerala, according to the Global Burden of Disease Study, 2018.

The authors also point to the higher levels of diabetes in the southern and eastern parts of India as being linked to diets of rice-meat-and-fish and a higher intake of sweets and snacks that were rich in trans-fats. These however weren't explanatory, the authors note. Being a cross-sectional survey, we found correlations not causation, Ms. Puri added.

You have reached your limit for free articles this month.

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Enjoy reading as many articles as you wish without any limitations.

A select list of articles that match your interests and tastes.

Move smoothly between articles as our pages load instantly.

A one-stop-shop for seeing the latest updates, and managing your preferences.

We brief you on the latest and most important developments, three times a day.

Not convinced? Know why you should pay for news.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

View post:
Prevalence of diabetes among women high in southern India - The Hindu

New research has found that eating dairy foods appears to be linked to a lower risk of diabetes and high blood pressure. An international team of researchers studied 147,812 participants aged between 35 and 70 from 21 countries: Argentina, Bangladesh, Brazil, Canada, Chile, China, Colombia, India, Iran, Malaysia, Palestine, Pakistan; Philippines, Poland, South Africa, Saudi Arabia, Sweden, Tanzania, Turkey, United Arab Emirates and Zimbabwe.

The participants completed Food Frequency Questionnaires which assessed how they ate over the last 12 months. Dairy products included milk, yogurt, yogurt drinks, cheese and dishes prepared with dairy foods, which were classified as full or low fat (1 to 2%). Butter and cream were analyzed separately because they are not commonly eaten in some of the countries in the study.

Other factors such as the participants medical history, use of prescription medicines, smoking status, measurements of weight, height, waist circumference, blood pressure and fasting blood glucose were also recorded. Participants were followed for an average of nine years.

The results showed that eating at least two servings of dairy each day is linked to an 11 to 12% lower risk of diabetes and high blood pressure, while three servings of total dairy each day are linked to a 13 to 14% lower risk. The associations were stronger for full-fat dairy than they were for low-fat dairy.

Two daily servings of total dairy were also linked to a 24% lower risk of metabolic syndrome, which is a collection of conditions that includes a higher waist circumference, high triglyceride levels, low levels of good cholesterol, hypertension (high blood pressure) and high fasting blood sugar, which together can increase the risk of cardiovascular disease. The relationship also was stronger for full-fat dairy; two servings of full fat were linked with a 28% lower risk of metabolic syndrome, compared with those who ate no dairy foods, and eating low-fat dairy was not associated with a lower prevalence of most of the conditions that make up metabolic syndrome.

The study is observational, so it does not prove a cause and effect relationship. However, if the findings are confirmed in sufficiently large and long-term trials, then eating more dairy foods may be an easy and inexpensive way to reduce metabolic syndrome, hypertension, diabetes and ultimately cardiovascular disease.

View post:
Extension notes: Eating dairy foods may lower the risk of diabetes and high blood pressure - The Herald Journal

Type 2 diabetes is a chronic condition that can be brought under control if one commits to a healthy lifestyle. The primary threat posed by type 2 diabetes is high blood sugar levels and by adding this food type to your breakfast meal you will not only help to lower blood sugar but it will also help you to lose weight.

In a study published in BMC Nutrition Journal, the effects of avocados on glucose and insulin levels in overweight adults was analysed.

The study noted: Avocados are nutrient dense with properties that may favourably impact energy balance.

This study sought to evaluate if incorporating approximately one half of a Hass avocado will influence glucose and insulin response, and subsequent energy intake among overweight adults.

The study concluded that those who consumed an avocado and a decreased desire to eat throughout the day which impacts weight management and insulin resistance.

Medical News Today said: When a person has diabetes, the foods they eat each day can impact how they feel and how well they control their condition.

In general, people with diabetes should eat foods that help control blood sugar levels and that offer health benefits such as lowering blood pressure and cholesterol.

This is one of the best ways to keep diabetes under control, avoid complications, and lead the healthiest life possible and avocados offer all these benefits, and possibly more.

Go here to see the original:
Type 2 diabetes: Adding this delicious food type to your breakfast will lower blood sugar - Express